+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 6Years - 11Years
All Genders
ID05222529

Evaluation of Glycopyrronium Bromide Doses Compared to Placebo in Children Aged 6 to Less Than 12 Years with Asthma Using a Randomized Crossover Design

Led by Novartis Pharmaceuticals · Updated on 2026-08-19

42

Participants Needed

23

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of inhaled glycopyrronium bromide in children aged 6 to less than 12 years with moderate to severe asthma. This Phase II study aims to compare two doses of glycopyrronium with a placebo to understand their bronchodilator effects, systemic exposure, safety, and tolerability. The results will help determine the appropriate dose for a fixed combination inhaler treatment for this pediatric population. The study is designed as a double-blind, placebo-controlled, randomized crossover trial with three treatments glycopyrronium bromide 12.5 g, glycopyrronium bromide 25 g, and placebo. Each participant receives all three treatments in different sequences over three two-week treatment periods separated by two-week washouts. Participants continue their background asthma controller therapy throughout. The total treatment phase lasts 10 weeks, preceded by screening and run-in phases, followed by a safety follow-up. Participants will undergo screening, followed by a run-in phase to confirm eligibility and assess inhaler technique. During treatment, lung function tests including forced expiratory volume in one second FEV1 are measured at the start and end of each treatment period. Pharmacokinetic samples, symptom assessments, rescue medication use, and adverse event monitoring occur regularly. Safety follow-up includes a telephone contact 30 days after the last treatment. The total study duration per participant is about 20 weeks.

CONDITIONS

Brief Title

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glycopyrronium (Bromide) in Children (6 to Less Than 12 Years) With Asthma

Research Team

N

Novartis Pharmaceuticals

N

Novartis Pharmaceuticals

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here